Fluorescence-Guided Surgery: Mechanisms, Clinical Evidence, and Practical Applications in Modern Surgical Oncology

Abstract

Fluorescence-guided surgery (FGS) represents a transformative advance in surgical oncology, leveraging targeted fluorescent probes to enhance intraoperative visualization of malignant tissues. By providing real-time, high-contrast delineation between tumor and normal structures, FGS improves the accuracy of tumor resections, reduces positive margin rates, and holds potential to optimize patient outcomes across various malignancies. This review synthesizes current scientific evidence, explores mechanistic underpinnings, discusses clinical applications, and evaluates emerging advances in FGS technology, with an emphasis on guideline-driven practice and implications for future research.

Introduction

Fluorescence-guided surgery (FGS) has rapidly emerged as a pivotal adjunct in oncologic and non-oncologic procedures. The technique utilizes exogenous or endogenous fluorophores that preferentially accumulate in neoplastic tissues, enabling surgeons to visualize tumors with enhanced specificity under dedicated imaging systems. While initially pioneered in neuro-oncology, FGS is now expanding into thoracic, abdominal, and urologic surgeries. This review aims to provide clinicians with a comprehensive overview of FGS, integrating mechanistic insights, epidemiological context, and the latest clinical evidence to inform best practices.

Epidemiology / Disease Burden

Oncologic surgery remains a cornerstone of cancer management, with an estimated 80% of solid tumors requiring surgical intervention at some stage. Despite advances in imaging and surgical technique, incomplete resections (positive margins) occur in up to 20-40% of cases for certain malignancies, contributing to local recurrence and reduced survival. The global burden of solid tumors continues to rise, with more than 19 million new cancer cases diagnosed annually. FGS directly addresses this unmet need by potentially reducing residual disease and improving long-term outcomes.

Pathophysiology

The pathophysiological rationale for FGS is founded on the differential uptake or binding of fluorophores by neoplastic versus non-neoplastic tissues. Tumors exhibit aberrant vascular permeability (enhanced permeability and retention effect), altered metabolic profiles, and distinct molecular markers, all of which can be targeted by specific fluorescent agents. Indocyanine green (ICG), 5-aminolevulinic acid (5-ALA), and antibody-fluorophore conjugates are among the most widely used agents, each exploiting unique tumor biology for intraoperative visualization.

Risk Factors

While FGS is broadly applicable across tumor types, certain patient and disease characteristics influence its utility and effectiveness. Risk factors for incomplete resection that may benefit from FGS include tumor location in eloquent or anatomically complex regions (e.g., brain, head and neck), infiltrative tumor margins, prior irradiation or surgery causing tissue distortion, and histologies with propensity for multicentric or microscopic spread. Patient-specific factors such as hepatic or renal impairment may also impact agent pharmacokinetics and fluorescence quality.

Clinical Features

Clinically, FGS is most valuable in scenarios where traditional visualization is limited. Features that favor FGS utility include poorly demarcated tumor margins, need for organ-sparing approaches, and intraoperative decision-making regarding extent of resection. In high-grade gliomas, for example, FGS using 5-ALA has been shown to identify otherwise occult tumor tissue, directly influencing surgical strategy and extent of resection. Similarly, in colorectal and hepatobiliary tumors, intraoperative fluorescence can highlight small lesions or metastatic deposits not detected on standard imaging.

Diagnosis

While FGS is primarily an intraoperative modality, its role in diagnosis is evolving. Preoperative imaging establishes surgical targets, but FGS provides real-time confirmation of tumor location and margins. Fluorophores may be administered systemically, topically, or locally depending on tumor type and location. Intraoperative imaging platforms, including modified surgical microscopes and laparoscopes, capture and display fluorescence signals, enabling precise tissue discrimination. Validation studies consistently demonstrate that FGS improves sensitivity and specificity for tumor identification compared to white-light surgery alone.

Treatment & Management

FGS is integrated into the surgical workflow as a decision-support tool. After administration of the fluorescent agent, surgeons use dedicated imaging systems to visualize the operative field. Fluorescent signal guides resection planes, identifies residual tumor, and aids in lymph node mapping or sentinel node biopsy. Protocols vary by indication and fluorophore, but the overarching goal is maximal safe resection with preservation of critical structures. In some settings, FGS may also facilitate minimally invasive or robotic approaches by compensating for limited tactile feedback.

Recent Advances / Emerging Therapies

Recent technological and pharmacological advances are rapidly expanding FGS capabilities. Novel targeted fluorophores, including antibody-based and peptide-based agents, offer greater specificity for tumor subtypes and molecular markers. Multiplexed imaging platforms can simultaneously detect multiple fluorophores, enabling characterization of tumor heterogeneity. Integration with artificial intelligence and machine learning is being explored to enhance real-time interpretation of fluorescence signals. Emerging applications extend beyond oncology, including perfusion assessment, visualization of nerves, and identification of infectious or ischemic tissues.

Guideline Recommendations

Professional societies increasingly recognize the value of FGS in select clinical scenarios. The European Association of Neuro-Oncology and the National Comprehensive Cancer Network endorse 5-ALA-guided resection for high-grade glioma as standard of care. Guidelines for hepatocellular carcinoma and colorectal cancer acknowledge the potential of ICG-based FGS for margin assessment and sentinel node mapping, though routine use remains investigational pending further evidence. Consensus emphasizes the need for standardized protocols, multidisciplinary collaboration, and rigorous outcome reporting to ensure safe and effective integration of FGS into clinical practice.

Conclusion

Fluorescence-guided surgery represents a paradigm shift in surgical oncology, offering enhanced visualization, improved margin status, and potential for better patient outcomes. Mechanism-based selection of fluorophores and tailored clinical application are critical for maximizing benefit while minimizing risks. Ongoing research into targeted agents, advanced imaging systems, and artificial intelligence integration promises to further refine and expand the role of FGS. As evidence accumulates and guidelines evolve, FGS is poised to become an indispensable tool for precision surgery across a broad spectrum of diseases.